Serial #88056022
LIVE

Serial Number

88056022

Owner

Vertisis Custom Pharmacy

Attorney

Karl S. Kronenberger

First Use Date

Nov 26, 2018

Filing Date

Jul 27, 2018

Add to watchlist:

No watchlists yet
View on USPTO

Serial #88056022 Trademark

Serial Number: 88056022 • Registration: 5789590

Serial #88056022 is a trademark filed by Vertisis Custom Pharmacy on July 27, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Vertisis Custom Pharmacy (5 trademarks)

9343 E Bahia Dr. Suite 200
Scottsdale, AZ 85260

Entity Type: 16

Trademark Details

Filing Date

July 27, 2018

Registration Date

June 25, 2019

First Use Anywhere

November 26, 2018

First Use in Commerce

November 26, 2018

Published for Opposition

January 15, 2019

Goods & Services

Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for chelation treatments; Medicinal preparations for promoting men's health, namely, treating erectile dysfunction, andropause, and male fertility, and performing testosterone replacement therapies; Medicinal preparations for promoting women's health, namely, treating menopause and female fertility; Medicinal preparations for hormone replacement therapy; Medicinal preparations for weight management; Medicinal preparations for prolotherapy treatments to treat inflammation, localized pain, generalized pain, and ligament laxity; Medicinal preparations for promoting animal health in the nature of infections, pain, inflammation, cancer, autoimmune disease, and ocular disease; Medicinal preparations for oncology treatments; Medicinal preparations for pain management; Prescription medicines, namely, intravenous pharmaceutical preparations for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Prescription medicines, namely, topical medications for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Prescription medicines, namely, custom compounded medications for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Prescription medicines, namely, custom compounded medications for intravenous administration for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Prescription medicines, namely, custom compounded medications for topical administration for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Prescription medicines, namely, custom compounded medications for nasal administration for weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, allergies, and neurotransmitter deficiencies; Medicinal preparations for the body to be applied in the form of intravenous fluids for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Medicinal preparations for the body to be applied in the form of topical ointments for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Medicinal preparations for the body to be applied in the form of nasal sprays for weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, allergies, and neurotransmitter deficiencies; Custom compounded medicinal preparations for the body to be applied in the form of intravenous fluids for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Custom compounded medicinal preparations for the body to be applied in the form of topical ointments for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Custom compounded medicinal preparations for the body to be applied in the form of nasal sprays for weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, allergies, and neurotransmitter deficiencies

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 7, 2025 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 7, 2025 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 16, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Jul 12, 2024 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 25, 2024 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 1, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 1, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 1, 2024 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 12, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 12, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 12, 2021 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 10, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 10, 2019 REAP
REGISTERED-PRINCIPAL REGISTER
Jun 25, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 24, 2019 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 23, 2019 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 22, 2019 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 21, 2019 AITU
USE AMENDMENT FILED
May 7, 2019 IUAF
TEAS STATEMENT OF USE RECEIVED
May 7, 2019 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 12, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 15, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jan 15, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 26, 2018 NONP
ASSIGNED TO LIE
Dec 6, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 16, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 16, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 16, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 16, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 16, 2018 CNEA
ASSIGNED TO EXAMINER
Nov 14, 2018 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 4, 2018 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2018 NWOS
NEW APPLICATION ENTERED
Jul 31, 2018 NWAP